Onxx pierced thru the 45 days moving avarage twice this week ($7 1/4)....I keep accumulating shares ahead of ASCO meetings. I expect good things for Onxx during ASCO especially regading Phase II trials of Onyx-015 for head and neck cancers.
Onxx currently has $5 per share in cash...You are only paying a $2 premuim for all the research. Onxx is too cheap. The downside for this stock is $6 to 6 1/4....The upside from ASCO could easily be $14 overnight.
Encouraged by Lehman's target fo $25 for the stock. Accumulated ahead of the news.
Now Long 8000 shares. I like management, the science, the cash, the new fund buyers joining the board, the industry partners, Lehmans target price, AND the ASCO meeting coming up shortly! I have verified the post on the ASCO book now being in oncologists hands-(just the abstract based on clinical data through December) Annual Report will be in shareholder hands shortly, and the company will be activating its website . Wouldn't be surprised to see National Media coverage if Clinical results continue to validate this revolutionary approach. Many of the weak holders likely to be washed out of the stock by now and current shareholders I assume will want to own more SOON.